NASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis $0.62 -0.03 (-4.58%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.61▼$0.6750-Day Range$0.63▼$3.0252-Week Range$0.36▼$5.83Volume604,702 shsAverage Volume1.79 million shsMarket Capitalization$34.15 millionP/E RatioN/ADividend YieldN/APrice Target$7.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Elevation Oncology alerts: Email Address Elevation Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,148.0% Upside$7.80 Price TargetShort InterestBearish12.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.86) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 starsMedical Sector729th out of 910 stocksBiological Products, Except Diagnostic Industry121st out of 155 stocks 3.5 Analyst's Opinion Consensus RatingElevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElevation Oncology has only been the subject of 3 research reports in the past 90 days.Read more about Elevation Oncology's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.80% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 4.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELEV. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Elevation Oncology this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for ELEV on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Elevation Oncology is held by insiders.Percentage Held by Institutions83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elevation Oncology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Elevation Oncology are expected to decrease in the coming year, from ($0.86) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Elevation Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Elevation Oncology Stock (NASDAQ:ELEV)Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Read More ELEV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELEV Stock News HeadlinesSeptember 3, 2024 | prnewswire.comElevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 16, 2024 | finance.yahoo.comElevation Oncology, Inc. (ELEV)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 13, 2024 | msn.comInfinyte.Club, HealthCRED, and MiClient Raise Seed FundingAugust 7, 2024 | markets.businessinsider.comElevation Oncology’s EO-3021 Shows Promising Efficacy and Safety in Gastric Cancer, Outperforming Market ExpectationsAugust 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Elevation Oncology (ELEV) and Harmony Biosciences Holdings (HRMY)August 6, 2024 | msn.comWhy Is Penny Stock Elevation Oncology Trading Lower On Tuesday?August 6, 2024 | seekingalpha.comElevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical ResultsSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 6, 2024 | msn.comElevation Oncology falls after early-stage data for lead cancer drugAugust 6, 2024 | prnewswire.comElevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsAugust 6, 2024 | prnewswire.comElevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2August 1, 2024 | markets.businessinsider.comMaintaining Buy Rating on MacroGenics: Assessing Vobra-duo’s Setbacks and Upcoming OpportunitiesJuly 24, 2024 | uk.finance.yahoo.comQ2 2024 Medpace Holdings Inc Earnings CallJuly 24, 2024 | seekingalpha.comMedpace Holdings, Inc. (MEDP) Q2 2024 Earnings Call TranscriptJune 27, 2024 | prnewswire.comElevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction CancerMay 14, 2024 | msn.comStephens & Co. Initiates Coverage of Elevation Oncology (ELEV) with Overweight RecommendationMay 7, 2024 | prnewswire.comElevation Oncology to Present at the Citizens JMP Life Sciences ConferenceSee More Headlines Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELEV CUSIPN/A CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,148.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.97% Return on Assets-38.49% Debt Debt-to-Equity Ratio0.38 Current Ratio41.10 Quick Ratio41.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.46Miscellaneous Outstanding Shares54,638,000Free Float50,212,000Market Cap$34.15 million OptionableOptionable Beta1.26 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Joseph J. Ferra Jr. (Age 49)CEO, President & Director Comp: $897.28kDr. David Dornan Ph.D. (Age 46)Chief Scientific Officer Comp: $620.92kMs. Valerie Malyvanh Jansen M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $685.94kMs. Tammy Furlong CPA (Age 53)P.M.P., CFO & Secretary Mr. Ryan BloomerHead of Tech OpsCandice MasseSenior Director of Corporate Communications & Investor RelationsMr. Robert C. YangVice President of Legal AffairsMr. Biren ShahSenior Vice President of Business & Corporate DevelopmentMore ExecutivesKey CompetitorsRain OncologyNASDAQ:RAINBolt BiotherapeuticsNASDAQ:BOLTSCYNEXISNASDAQ:SCYXStrongbridge BiopharmaNASDAQ:SBBPAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Sold 1,687,970 shares on 8/19/2024Ownership: 3.075%Frazier Life Sciences Management L.P.Bought 2,958,579 shares on 8/16/2024Ownership: 5.415%Darwin Global Management Ltd.Sold 416,638 shares on 8/15/2024Ownership: 3.507%Affinity Asset Advisors LLCBought 200,000 shares on 8/15/2024Ownership: 2.688%Marshall Wace LLPSold 94,958 shares on 8/14/2024Ownership: 0.069%View All Institutional Transactions ELEV Stock Analysis - Frequently Asked Questions How have ELEV shares performed this year? Elevation Oncology's stock was trading at $0.5370 at the beginning of 2024. Since then, ELEV stock has increased by 16.4% and is now trading at $0.6250. View the best growth stocks for 2024 here. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share. Who are Elevation Oncology's major shareholders? Top institutional investors of Elevation Oncology include Logos Global Management LP (7.05%), Farallon Capital Management LLC (6.59%), Frazier Life Sciences Management L.P. (5.41%) and Darwin Global Management Ltd. (3.51%). View institutional ownership trends. How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELEV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELEV Stock Alerts